Patients' experiences with pre-test genetic counseling provided by breast cancer healthcare professionals : Results from a large prospective multicenter study
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Pre-test genetic counseling of patients with breast cancer is increasingly being offered by non-genetic healthcare professionals. We aimed to evaluate the experiences of patients with breast cancer receiving pre-test genetic counseling from a non-genetic healthcare professional (i.e., surgeon or nurse).
METHODS: Patients who were diagnosed with breast cancer and received pre-test counseling from their surgeon or nurse (mainstream group), and patients who received pre-test counseling from a clinical geneticist (usual care group) were invited to participate in our multicenter study. Between September 2019 and December 2021, patients received a questionnaire after pre-test counseling (T0) and four weeks after receiving their test results (T1) to evaluate psychosocial outcomes, knowledge, discussed topics and satisfaction.
RESULTS: We included 191 patients in our mainstream and 183 patients in our usual care group and received, respectively 159 and 145 follow-up questionnaires. Levels of distress and decisional regret were comparable in both groups. Decisional conflict was higher in our mainstream group (p = 0.01), but only 7% had clinically relevant decisional conflict (vs 2% in usual care group). The possible implications of a genetic test on (secondary) breast or ovarian cancer risks were less frequently discussed in our mainstream group (p = 0.03 and p = 0.000, respectively). In both groups knowledge about genetics was comparable, satisfaction was high and the majority of patients in both groups preferred to give both verbal and written consent for genetic testing.
CONCLUSION: Mainstreamed genetic care provides sufficient information for the majority of breast cancer patients to decide about genetic testing with minimal distress.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Breast (Edinburgh, Scotland) - 69(2023) vom: 15. Juni, Seite 349-357 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bokkers, K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Completed 16.06.2023 Date Revised 16.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.breast.2023.03.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355236710 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355236710 | ||
| 003 | DE-627 | ||
| 005 | 20231226063926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.breast.2023.03.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355236710 | ||
| 035 | |a (NLM)37018966 | ||
| 035 | |a (PII)S0960-9776(23)00434-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bokkers, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patients' experiences with pre-test genetic counseling provided by breast cancer healthcare professionals |b Results from a large prospective multicenter study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.06.2023 | ||
| 500 | |a Date Revised 16.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Pre-test genetic counseling of patients with breast cancer is increasingly being offered by non-genetic healthcare professionals. We aimed to evaluate the experiences of patients with breast cancer receiving pre-test genetic counseling from a non-genetic healthcare professional (i.e., surgeon or nurse) | ||
| 520 | |a METHODS: Patients who were diagnosed with breast cancer and received pre-test counseling from their surgeon or nurse (mainstream group), and patients who received pre-test counseling from a clinical geneticist (usual care group) were invited to participate in our multicenter study. Between September 2019 and December 2021, patients received a questionnaire after pre-test counseling (T0) and four weeks after receiving their test results (T1) to evaluate psychosocial outcomes, knowledge, discussed topics and satisfaction | ||
| 520 | |a RESULTS: We included 191 patients in our mainstream and 183 patients in our usual care group and received, respectively 159 and 145 follow-up questionnaires. Levels of distress and decisional regret were comparable in both groups. Decisional conflict was higher in our mainstream group (p = 0.01), but only 7% had clinically relevant decisional conflict (vs 2% in usual care group). The possible implications of a genetic test on (secondary) breast or ovarian cancer risks were less frequently discussed in our mainstream group (p = 0.03 and p = 0.000, respectively). In both groups knowledge about genetics was comparable, satisfaction was high and the majority of patients in both groups preferred to give both verbal and written consent for genetic testing | ||
| 520 | |a CONCLUSION: Mainstreamed genetic care provides sufficient information for the majority of breast cancer patients to decide about genetic testing with minimal distress | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Genetic counseling | |
| 650 | 4 | |a Mainstream genetic testing | |
| 650 | 4 | |a Patients' perspectives | |
| 650 | 4 | |a Psychosocial outcomes | |
| 650 | 4 | |a Satisfaction | |
| 700 | 1 | |a Bleiker, E M A |e verfasserin |4 aut | |
| 700 | 1 | |a Velthuizen, M E |e verfasserin |4 aut | |
| 700 | 1 | |a Koelemij, R |e verfasserin |4 aut | |
| 700 | 1 | |a Burgmans, J P J |e verfasserin |4 aut | |
| 700 | 1 | |a Klinkenbijl, J H |e verfasserin |4 aut | |
| 700 | 1 | |a Schouten van der Velden, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Vermulst, N |e verfasserin |4 aut | |
| 700 | 1 | |a Huizinga, B F |e verfasserin |4 aut | |
| 700 | 1 | |a Witkamp, A J |e verfasserin |4 aut | |
| 700 | 1 | |a Frakking, T |e verfasserin |4 aut | |
| 700 | 1 | |a Brohet, R M |e verfasserin |4 aut | |
| 700 | 1 | |a Aalfs, C M |e verfasserin |4 aut | |
| 700 | 1 | |a Koole, W |e verfasserin |4 aut | |
| 700 | 1 | |a Schoenmaeckers, E J P |e verfasserin |4 aut | |
| 700 | 1 | |a Ausems, M G E M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast (Edinburgh, Scotland) |d 1997 |g 69(2023) vom: 15. Juni, Seite 349-357 |w (DE-627)NLM091676371 |x 1532-3080 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2023 |g day:15 |g month:06 |g pages:349-357 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.breast.2023.03.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2023 |b 15 |c 06 |h 349-357 | ||